IVA Inventiva S.A. IFRS Annual reports only
Pharmaceutical Preparations · Nasdaq · SEC CIK 1756594 · Reporting currency EUR · Fiscal year ends 12/31
Financial factors as of 2023-12-31 (FY2023), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: EUR | FY2024*2024-12-31 | FY2023*2023-12-31 | FY2022*2022-12-31 | FY2021*2021-12-31 | FY2020*2020-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | 9.20M | 17.48M | 12.18M | 4.19M | 372,000 |
| R&D expense | 90.88M | 110.01M | 60.47M | 48.45M | 23.72M |
| SG&A expense | 15.84M | 13.84M | 12.91M | 11.15M | 8.50M |
| Operating income | -97.56M | -102.71M | -57.11M | -52.11M | -29.72M |
| Interest expense | 12.18M | 5.18M | 584,000 | 138,000 | 66,000 |
| Income tax | 313,000 | 607,000 | -20,000 | 364,000 | 0 |
| Net income | -184.21M | -110.43M | -54.27M | -49.63M | -33.62M |
| EPS (basic) | -3.08 | -2.43 | -1.31 | -1.27 | -0.99 |
| EPS (diluted) | -3.08 | -2.43 | -1.31 | -1.27 | -0.99 |
| Weighted avg. shares (diluted) | 59.78M | 45.35M | 41.45M | 39.17M | 33.87M |
| Balance sheet | |||||
| Cash & equivalents | 96.56M | 26.92M | 86.74M | 86.55M | 105.69M |
| Short-term investments | — | 10,000 | 1.00M | 8.80M | — |
| Receivables | 531,000 | 3.81M | 0 | 4.00M | 48,000 |
| Inventory | 0 | 417,000 | 373,000 | 392,000 | 320,000 |
| Current assets | 111.51M | 48.19M | 106.38M | 115.58M | 133.00M |
| PP&E, netmay include right-of-use assets (IFRS) | 5.00M | 9.12M | 7.39M | 3.20M | 3.28M |
| Intangibles | 48,000 | 541,000 | 568,000 | 770,000 | 935,000 |
| Total assets | 118.97M | 69.56M | 116.00M | 121.98M | 138.92M |
| Current liabilities | 120.73M | 50.16M | 30.70M | 22.85M | 13.91M |
| Short-term debt | — | — | 5.85M | 1.28M | 18,000 |
| Long-term debt | — | — | 28.66M | 8.84M | 10.04M |
| Total debt | — | — | 34.51M | 10.12M | 10.05M |
| Total liabilities | 225.61M | 101.59M | 70.53M | 33.12M | 27.71M |
| Shareholders' equity | -106.65M | -32.03M | 45.48M | 88.87M | 111.21M |
| Net debt | — | — | -52.22M | -76.43M | -95.63M |
| Shares outstanding | 95.66M | 52.12M | 42.13M | 40.87M | 38.63M |
| Cash flow statement | |||||
| Operating cash flow | -85.93M | -81.61M | -44.93M | -47.63M | -30.59M |
| Investing cash flow | 8.74M | -7.73M | 8.87M | -1.79M | -8.56M |
| Financing cash flow | 145.59M | 29.08M | 37.27M | 25.45M | 111.67M |
| Stock-based compensation | 3.58M | 3.97M | 2.22M | 2.09M | 938,000 |
Free plan shows the latest 5 periods; Pro shows all 7 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· This company does not report gross profit in XBRL.
· Amounts are in the company's reporting currency, EUR, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.